FIGURE 2.

VDAC1 transmembrane topology models showing the sites of mutated amino acids, the sequences used for synthetic peptide synthesis, and the proposed domains interacting with Bcl-2. The previously proposed transmembrane topology of VDAC1 (modified from Ref. 20) (A) and a revised model based on the newly proposed structure (28–30) are shown (B). The sequences of peptides (labeled in light gray) expressed or synthesized as synthetic peptides and tested in this work are illustrated. The black circles around Glu⁶⁵, Glu⁷², and Glu²⁰² and E65Q indicate mutations in mVDAC1 used in this study and were found to eliminate Bcl-2-mediated antiapoptotic activity. The dark gray lines indicate VDAC1 sequences interacting with Bcl-2 in the peptide array experiment (Fig. 7C).